Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks. Dosing
was initiated immediately following engraftment (between Days 14-30 post-transplant) to
prevent/control cytomegalovirus (CMV) infection or prevent disease in R+ hematopoietic stem
cell transplant (HCT) recipients.